Continuum Therapeutics reported its second-quarter 2026 financial results, announcing it has streamlined its discovery programmes to focus on inflammatory and fibrotic diseases. This resulted in a workforce reduction, including the departure of Chief Scientific Officer Daniel Lorrain. The company's global Phase 2 PROPEL-IPF trial evaluating PIPE-791 for idiopathic pulmonary fibrosis now has over 55 sites online across eight countries. Johnson & Johnson completed enrollment of 107 participants in June 2026 for its Phase 2 trial of JNJ-5120/PIPE-307 in major depressive disorder. Cash and marketable securities totalled $236.6 million as of 30 June 2026, which the company projects will fund operations through mid-2029. Research and development expenses decreased 10% to $12.7 million year-on-year, whilst general and administrative expenses rose 23% to $4.7 million. Net loss was $15.2 million for the quarter.

Contineum Therapeutics, a clinical-stage biopharmaceutical company, reported first-quarter 2026 financial results with $246.3 million in cash, cash equivalents and marketable securities as of 31 March 2026. The company believes this provides a cash runway through mid-2029. The company recently reported positive topline results from an exploratory Phase 1b trial of PIPE-791 for chronic pain treatment, meeting its primary safety and tolerability objectives. Contineum has initiated patient dosing in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for idiopathic pulmonary fibrosis in approximately 324 patients. Research and development expenses decreased 15% to $11.6 million compared to the first quarter of 2025. Net loss was $14.5 million for the three months ended 31 March 2026, versus $16.0 million in the prior-year period.